The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1333-1342.e1, December 2009

Selective control of SIRP-α–positive airway dendritic cell trafficking through CD47 is critical for the development of TH2-mediated allergic inflammation

  • Marianne Raymond, MSc

      Affiliations

    • Immunoregulation Laboratory, Centre Hospitalier de l'Université de Montréal Research Center, Hôpital Notre-Dame, Montreal, Quebec, Canada
  • ,
  • Manuel Rubio, BSc

      Affiliations

    • Immunoregulation Laboratory, Centre Hospitalier de l'Université de Montréal Research Center, Hôpital Notre-Dame, Montreal, Quebec, Canada
  • ,
  • Geneviève Fortin, BSc

      Affiliations

    • Immunoregulation Laboratory, Centre Hospitalier de l'Université de Montréal Research Center, Hôpital Notre-Dame, Montreal, Quebec, Canada
  • ,
  • Karim Hamdy Shalaby, BSc

      Affiliations

    • Meakins-Christie Laboratories, McGill University, Montreal, Quebec, Canada
  • ,
  • Hamida Hammad, PhD

      Affiliations

    • Laboratory of Immunoregulation, University of Ghent, Ghent, Belgium
  • ,
  • Bart N. Lambrecht, MD, PhD

      Affiliations

    • Laboratory of Immunoregulation, University of Ghent, Ghent, Belgium
  • ,
  • Marika Sarfati, MD, PhD

      Affiliations

    • Immunoregulation Laboratory, Centre Hospitalier de l'Université de Montréal Research Center, Hôpital Notre-Dame, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Marika Sarfati, MD, PhD, Immunoregulation, Laboratory, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame (Pavillon Mailloux, M4211K), 1560 Sherbrooke Street East, Montreal, Québec H2L 4M1, Canada.

Received 13 May 2009; received in revised form 9 July 2009; accepted 9 July 2009. published online 14 September 2009.

Background

Dendritic cells (DCs) are essential for the initiation and maintenance of TH2 responses to inhaled antigen that lead to the establishment of allergic diseases. Two subpopulations of nonplasmacytoid DCs (ie, CD11blowCD103+ and CD11bhighCD103-) are found in lung/airway tissues. Yet the identification and migratory properties of the DC subset that contributes to TH2-mediated responses remain to be clarified. CD47, a signal regulatory protein (SIRP)–α partner, reportedly governed skin DC migration.

Objective

We here thought to investigate the role of CD47/SIRP-α interactions in airway DC trafficking and the development of allergic airway inflammation.

Methods

We characterized the DC influx into lungs and mediastinal lymph nodes in CD47-/- and CD47+/+ BALB/c mice by using experimental models of allergic asthma. Mice were systemically (intraperitoneal ovalbumin/alum) or locally (intratracheal ovalbumin-loaded bone marrow–derived DCs) immunized and challenged by ovalbumin aerosol. We also evaluated the consequences of SIRP-α-Fc fusion molecule administration on the induction of airway disease in BALB/c mice.

Results

SIRP-α selectively identified the CD11bhighCD103- DC subset that predominantly accumulated in mediastinal lymph nodes during airway inflammation. However, CD103-SIRP-α+ DC trafficking, TH2 responses, and airway disease were impaired in CD47-/- mice. Importantly, the adoptive transfer of CD103- SIRP-α+CD47+/+ but not CD47-/- DCs elicited a strong TH2 response in CD47-/- mice. Finally, the administration of SIRP-α-Fc molecule protected BALB/c mice from allergic airway inflammation.

Conclusion

Lung CD11bhighCD103-SIRP-α+ DC migration is governed by self-CD47 expression, and manipulation of the CD47/SIRP-α pathway suppresses CD103-SIRP-α+ DC-driven pathogenic TH2 responses and airway inflammation.

Key words: Dendritic cells, migration, CD103, allergic inflammation, TH2, CD47, SIRP-α

Abbreviations used: BALF, Bronchoalveolar lavage fluid, BMDC, Bone marrow–derived dendritic cell, DC, Dendritic cell, FITC, Fluorescein isothiocyanate, Foxp3, Forkhead box protein 3, LN, Lymph node, MFI, Mean fluorescence intensity, mLN, Mediastinal lymph node, pDC, Plasmacytoid dendritic cell, SIRP, Signal regulatory protein

 

 Supported by the Canadian Institute for Health and Research (CIHR Grant, MOP-53152).

 Disclosure of potential conflict of interest: B. N. Lambrecht has served as a consultant for Merck Serono and NovImmune. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01089-6

doi:10.1016/j.jaci.2009.07.021

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1333-1342.e1, December 2009